New FDA rules for medical device makers

Today's Big News

Mar 29, 2023

Clinical trial diversity craters out to lowest level in 10 years, IQVIA finds


Bluebird bio lays gene therapy launch groundwork as sickle cell application nears


Under a new law, FDA submissions must prove that medical devices meet cybersecurity standards


J&J scraps late-stage RSV vaccine in R&D overhaul, dropping out of race with GSK, Pfizer


Emergent makes history with first FDA nod for over-the-counter naloxone


ICU Medical faces off with GE HealthCare, others in bids for Medtronic spinout deal: Reuters

 

Featured

Clinical trial diversity craters out to lowest level in 10 years, IQVIA finds

While clinical trial activity was strong in 2022 following a pandemic-induced dip, many trends resumed their pre-COVID trajectory—including plummeting diversity in clinical trials.
 

Top Stories

Bluebird bio lays gene therapy launch groundwork as sickle cell application nears

While commercial revenue has yet to materialize in bluebird bio's earnings report, the company is flying high on the U.S. launches of its two new gene therapies Zynteglo and Skysona.

Under a new law, FDA submissions must prove that medical devices meet cybersecurity standards

The FDA's new cybersecurity requirements went live Wednesday, as a $1.7 trillion federal omnibus spending bill took effect.

J&J scraps late-stage RSV vaccine in R&D overhaul, dropping out of race with GSK, Pfizer

Johnson & Johnson is 'exiting' a late-stage respiratory syncytial virus program amid a large-scale overhaul of its infectious disease unit. 

Emergent makes history with first FDA nod for over-the-counter naloxone

The U.S. FDA blessed Emergent BioSolutions' 4mg Narcan nasal spray with a nonprescription nod, teeing up over-the-counter sales for the opioid overdose reversal treatment at places like drug stores, convenience stores, supermarkets and gas stations.

ICU Medical faces off with GE HealthCare, others in bid for Medtronic spinouts: Reuters

ICU Medical has placed itself in the running to serve as the new corporate home of Medtronic’s patient monitoring and hospital ventilator businesses, according to a report from Reuters.

Blueprint's solid tumor med permitted to resume phase 1/2 testing after partial hold lifted

Blueprint Medicines’ solid tumor med BLU-222 is back from the drawing board after the FDA lifted a partial clinical hold that has been in place since mid-February.

After drug rejection, Vanda scores courtroom win over FDA in records case

Vanda Pharmaceuticals has scored a legal win over the FDA. A D.C. District Court ruled that the agency must turn over records relating to its 2018 rejection of the company's Hetlioz in jet lag disorder.

Pharmaron snares UK grant to scale out cell and gene facility it bought from AbbVie

A major makeover is underway at a former AbbVie biologics plant in Liverpool, which Pharmaron bought in 2021. The work is supported by a U.K. government grant, the Chinese CDMO said.

Getinge temporarily loses another CE mark, this time for recently recalled heart balloon pumps

Only a month after Getinge announced that the CE marks allowing it to sell its heart-lung support and permanent life support systems in Europe had been suspended, the Swedish devicemaker has temporarily lost another EU approval.

AstraZeneca pulls pneumonia collab with Aridis over allegations of a missed payment

AstraZeneca has pulled out of a pneumonia collaboration with Aridis Pharmaceuticals, sending the biotech’s phase 3 plans into a tailspin over the company’s alleged failure to hand over the agreed upfront payment two years ago.

#FierceMadness 2023: Intra-Cellular’s Caplyta ad lights the way, now vote for your Final Four bracket

If it’s March, it must be #FierceMadness, Fierce Pharma Marketing’s annual take on the March Madness NCAA basketball tournament and bracket mania—with a pharma twist.
 
Fierce podcasts

Don't miss an episode

'The Top Line': Fierce Medtech's annual Fierce 15 honorees, plus this week's headlines

This week on "The Top Line," we discuss Fierce Medtech’s annual Fierce 15 report and startups that made the cut. We also cover Illumina and Carl Icahn's proxy battle and more of this week's top headlines.
 

Resources

Whitepaper

Plan for scalable process liquid and buffer preparation

Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation.
Whitepaper

US/EU Governance: The Importance of Company Culture and Proven, Real-World Solutions

This paper describes the key elements of good US/EU corporate governance for US-based biopharma companies in operating Europe.
Executive Summary

Optimizing drug discovery in a fast-moving market

Read about the latest survey results from over 200 biopharma executives and the changing approaches to building biologic drug development pipelines.
Whitepaper

Answering your specific questions about mRNA/saRNA manufacturing

Have you had your questions about mRNA/saRNA manufacturing unanswered during a webinar; have no fear, we have you covered here.
Whitepaper

Proven Pharmaceutical Go-To-Market Model

Download Herspiegel Consulting’s Go-To-Market Model, based on 100+ launches, to learn the critical components, and timelines for commercial success.

Whitepaper

Intranasal Drug Product Development: Formulation to Manufacturing

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?
Whitepaper

Running Decentralized Trials at Scale

Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment.
Research

Step-wise strategy to address process characterization and late phase development

Learn more on Catalent’s step-wise approach for the definition and execution of Process Characterization for the production of a monoclonal antibody for late phase process characterization and development.

Case Study

A Strategy to Standardize Process Characterization & Late Phase Development

Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments.

Whitepaper

Designing an Optimal APAC Clinical Supply Chain

Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific.
Whitepaper

Key Clinical Supply Issues Sponsors Should Consider with their CRO

As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs.

Research

A Strategy to Standardize Process Characterization & Late Phase Development

Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments.

Whitepaper

Specialized Expertise for Management of Clinical Supply Budgets

For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management.
Whitepaper

Clinical Supply Solutions for the Asia-Pacific Region

Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region.
Whitepaper

Roles and Responsibilities of Specialized Clinical Supply Experts

How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis.
Whitepaper

Questions You Need to Ask Your CRO About Clinical Supply

Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial.
Whitepaper

Supply Services to Support Clinical Trials in Japan & Beyond

Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world.
 

Industry Events

 

Upcoming Fierce Events

3-4
Apr
San Diego, CA
1-3
May
May 1-3, 2023 | Jersey City, NJ
12-14
Jun
San Diego, CA
13-14
Jun
Free Virtual Event
20-22
Jun
Free Virtual Event

View all events